ideasIdea

Extend Medicare's inflation rebates to employer plans

Since 2023 manufacturers must rebate Medicare when a drug's price rises faster than inflation; applying the same rule to commercial plans would end the yearly list-price rises that drive coinsurance up.

The Inflation Reduction Act of 2022 requires manufacturers to pay rebates on Part B and Part D drugs whose prices rise faster than the consumer price index. Commercial plans have no such protection, and oncology drugs have historically had annual list-price increases well above inflation. Extending the rebate to the commercial market, or letting employers piggyback on the Medicare calculation, would cap post-launch price growth across the whole system.

Hypothesis

Commercial inflation rebates will hold post-launch list-price growth for oncology drugs to the rate of general inflation within two years of enactment, with launch prices rising less than the rebate saves.

Rationale

The Medicare rebate has already reduced price increases for affected drugs according to CMS; the commercial market is where most working-age patients with cancer are insured.

What would test it

Compare list-price trajectories of oncology drugs before and after the Medicare rebate took effect, then model and pilot the commercial extension in a state with an all-payer claims database.

Maturity

speculative

Who has to act

policy

Cost to try

Medium ($1M to $50M)

Years to first evidence

Bottlenecks it attacks

Prices and value · New cancer drugs routinely cost over $150,000 a year, often for months of benefit. Systems cannot afford them and patients go bankrupt.